Right ventricular pacing (RVP) is the default for patients with AV block and normal LV function, because it’s simple, ...

Heartflow, the AI plaque analysis and FFR-CT incumbent, has once again taken the legal route to defend its cardiac CT ...

Functional decline and frailty in older heart failure patients can rapidly decrease their lifespan and it’s hard to quantify ...

Ladies and gents, it’s that time of year again where we take a look at MedAxiom’s Annual Cardiovascular Provider Compensation ...

A study in JAMA Cardiology found that broader genetic tests are better at identifying patients with cardiomyopathies and arrhythmias than disease-specific tests, despite perceived drawbacks. Currently ...

A study published in Science found that the loss of the Y chromosome, which occurs naturally in many men as they age, can cause heart scarring and premature death. Scientists have known for half a ...

One of imaging AI’s hottest segments just got even hotter with the completion of Us2.ai’s $15M Series A round and the global launch of its flagship echocardiography AI solution. It’s been at least a ...

Antiplatelet medications and beta blockers can improve survival and quality of life for people with cardiovascular disease. But those protections may come with added risk on hot summer days. A study ...

Despite society guidelines and extensive clinical evidence demonstrating that traditional wire-based coronary physiology improves outcomes and reduces costs compared to angiography alone 1-2, ...

With all the talk of AI outperforming and replacing doctors, a new JACC study reminds us – AI diagnostic algorithms don’t perform great when applied to populations different from the ones they’re ...

Children born with congenital pulmonary valve disease no longer need repeat surgeries throughout childhood with the FDA approval of Edwards Lifesciences’ Autus Size-Adjustable Valve. Enter the Autus ...

It’s not surprising that Alnylam’s Amvuttra (vutrisiran) received FDA approval for ATTR-CM last week, but what shocked many was Alnylam’s choice to price the drug at nearly half a million dollars per ...